CMMB vs RTX · $22.2M cap vs P/E 36, rev $46.78B
Chemomab Therapeutics Ltd DRC (CMMB) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Chemomab Therapeutics Ltd DRC (CMMB) is a biotechnology company listed on US.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
CMMB does not have a complete income-statement cache yet.
Latest reported RTX revenue for 2026-06-30 was $46.78B. Net income was $4.20B. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
CMMB currently screens at market cap $22.2M. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the CMMB and RTX stock pages for the full models.
Not investment advice.